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Various types of porous resins adsorbents based on polystyrene, polyvinyl alcohol, cellulose as matrixes and DNA, amino acids 
with other biological active molecules as ligands were extensively studied at Nankai University. Molecular recognition between 
the ligand and pathogenic molecule was investigated. Several commercialized products are now widely used in hospitals all over 
China. Whole blood hemoperfusion are used to treat patients suffering from autoimmune diseases, uremia acute intoxication and 
hyperbilirubinemia. Clinical performances of hundreds and thousands of patients，treated by whole blood sorption therapy are safe, 
efficient (90%) and cost-effective.  
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In the early 1980s, a research group headed by Professor Yu 
was established at Nankai University and aimed to synthe-
size various types of adsorbents for the therapy of severe 
diseases, which conventional medical treatments show little 
or no efficiency. Bioactive ligands such as DNA and amino 
acids were carefully designed and linked to porous resins of 
polystyrene, polyvinyl alcohol, and cellulose. The adsor-
bents thus made were used to selectively remove pathogenic 
molecules in blood of patients suffering from auto-immune 
diseases, liver, kidney failure, hyperlipidemia, endotoxemia 
and acute intoxication by hemoperfusion. In order to reduce 
the burden of health-care agencies and enabling a large 
number of patients to be treated in the hospitals, the Nankai 
group used whole blood perfusion instead of plasmapheresis 
in hemoperfusion. Therefore, biocompatible adsorbents were 
carefully designed and tailor made for the safety of the 
treatment.  
The present paper mainly focused on the development, 
commercialization and clinical performance of various 
kinds of adsorbents in sorption perfusion.  
1  Polystyrene based adsorbent 
1.1  Carbonized resin immobilized DNA 
In 1983 carbonized resin beads was made by the Nankai 
group from a styrene copolymer by pyrolysis at high tem-
perature. DNA was then coated on the resin with a collodi-
on solution to form an immuno-adsorbent. Whole blood 
from systemic lupus erythematosus (SLE) patients was per-
fused through a cartridge containing the immuno-adsorbent. 
Clinical reports of 23 patients showed that the pathogenic 
anti-DNA antibody was removed at an average of 56%, im-
muno-complexes were sharply reduced and symptoms were 
relieved. After perfusion no significant changes in hemoglo-
bin, leukocyte count, total protein and electrolytes were ob-
served. Platelet depletion was in the permissible range. 
Whole blood hemoperfusion with the immuno-adsorbent was 
effective (90%) for treatment of SLE and the commercialized 
cartridges are now used in hospitals all over China [1–9].  
1.2  Large pore-size porous resin 
Various macroporous resins were tailor-made by suspension 
Innovative Biomaterials and Crossing Frontiers in Biomaterials and Regenerative Medicine 
4358 Yu Y T   Chin Sci Bull   December (2013) Vol.58 No.35 
 
polymerization of styrene and divinyl benzene with various 
amounts of pore-forming materials at Nankai University. 
Resins with different pore diameters and surface areas were 
studied for the adsorption capacity of unconjugated biliru-
bin (Table 1).  
From the data shown above, we can clearly see that NK- 
110 resin having a pore size of 160 Å and surface area of 
500 m2/g showed the highest adsorption capacity for biliru-
bin. This is because the large size of the unconjugated bili-
rubin molecule could diffuse freely through the large pores 
of the resin. This does not mean that the larger the pore size, 
the higher adsorption capacity, because as the pore size in-
creases the surface area decreases, resulting in a decrease of 
adsorption capacity. Therefore a balance between the two 
parameters should be optimized in order to obtain the high-
est adsorption capacity. From the above findings, a slightly 
modified resin was commercialized and successfully used in 
clinics for the treatment of hyperbilirubinemia patiemts in 
whole blood hemoperfusion [10]. 
1.3  High surface area resin 
High surface area of 1076 m2/g porous resin was made from 
polystyrene by the Nankai group [11]. The bead type porous 
resin has a high adsorption capacity for small molecules 
such as drugs and chemicals (Table 2).  
The physiological and blood compatible properties of the 
adsorbent were approved by China Food and Drug Admin-
istration (SFDA). The resin is now produced on an industri-
al scale and used clinically for detoxification of acute in-
toxicated patients in hospitals all over China. 
2  Cellulose based adsorbent 
Cellulose is a natural biomaterial that is biodegradable and 
has good biocompatibility properties. Various adsorbents 
based on cellulose as matrixes were extensively studied 
(Table 3). An adsorbent for the removal of bacterial endo-
toxins was developed by immobilizing lysine covalently 
onto cellulose beads [12]. In vivo studies showed that the 
mean blood endotoxin concentration in rabbits was reduced 
significantly from 5.56±0.54 to 0.41±0.26 EU/mL after 
perfusion without significant side effects. It has a high po-
tential of clinical application for treatment of endotoxemia 
patients [13].  
Another approach showed cellulose beads linked with 
phenylalanine ligand can remove rheumatoid factors [14]. 
In vivo results show that the adsorbent holds promise as a 
highly effective and safe adsorbent in clinical therapy for 
rheumatoid arthritis patients by hemoperfusion [15]. It is 
well known that dendrimers have a large number of termi-
nal functional groups. A synthetic approach involved arch-
ing of PAMAM onto cellulose beads by reaction with 
epichlorohydrin was conducted [16]. The adsorbent showed 
a high amount of ligands linked and an enhanced adsorption 
percentage for rheumatoid factors [17].  
In order to remove the anti-DNA antibody from the blood 
of patients with systematic lupus erythematosus (SLE), DNA 
immuno-adsorbent was prepared by coupling calf thymus 
DNA to epichlorohydrin-activated cellulose beads. In vitro 
adsorption tests showed that the DNA immuno-adsorbent 
could remove 40%–70% of anti-DNA antibody from the 
plasma (incubation of 1.0 mL of adsorbent with 3.0 mL of 
plasma) [18]. In the circulation tests, 30 mL of plasma was 
circulated through a column containing 3 mL of adsorbent. 
The maximum decrease of anti-DNA level was 80% after 
60 min. The high adsorption capacity and rate suggest the 
immuno-adsorbent may be used for clinical treatment [19].  
Immuno-adsorbents for removing pathogenic antibodies 
of myasthenia gravis were prepared by coupling tryptophan 
onto cellulose beads. In vivo hemoperfusion experimental  
Table 1  Various surface area and pore size of resins versus their adsorption capacity for bilirubin 
 Resin Specific surface area (m2/g) Average pore size (Å) Adsorption capacity (%) 
Average pore diameter  
larger than 120 Å 
NK-X-5110 500 160 87.5 
X-5 483 152 79.3 
A-6 330 125 41.0 
A-7 200 250 28.0 
D-14 38 500 22.0 
Average pore diameter  
lower than 120 Å 
Amberlite XAD-4 750 50 16.7 
D-6 466 73 29.0 
58-9 388 43 13.8 
Amberlite XAD-2 300 90 12.0 















Adsorption capacity (%) 
Chlorpromazine Barbital Methaqualone Valium 
NK-107 0.37 1086 90 64 1.27 0.6–1.2 88.7 90.6 94.8 82.9 
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Table 3  Cellulose based adsorbent 
Ligands Pathogenic molecules Adsorptionefficacy (%)
Lysine Endotoxin 80 
Phenylalanine Rheumatoid factors 60 
Calf thymus DNA Anti-DNA antibody 70 
Tryptophan Acetylcholine receptor antibodies 25 
Phosphate Low density lipoprotein 3.12a) 
Taurine Low density lipoprotein 57 
Cholesterol and sulfonic Low density lipoprotein 88 
a) Adsorption capacity (mg/mL). 
results showed that the removal of acetylcholine receptor 
antibodies was 25% [20,21].  
Hyperlipidemia is one of high risk for the development 
of atherosclerosis. In order to remove high levels of low 
density lipoprotein (LDL), especially in familial hypercho-
lesterolemia patients, cellulose based LDL adsorbent with 
phosphate functional groups was prepared. The adsorption 
capability was 3.12 mg/mL, which proved the phosphate 
adsorbent had high adsorption capability and excellent ad-
sorption selectivity. The autoclave and storage test showed 
the adsorbent was stable [22]. Cellulose based LDL adsor-
bent with taurine functional group and PAMAM spacer also 
showed high adsorption capacity for LDL [23]. 
In order to enhance the adsorption capacity of the devel-
oped adsorbent, a new amphiphilic adsorbent for the re-
moval of LDL was prepared by introducing cholesterol and 
sulfonic groups onto cellulose beads [24,25]. In vitro studies 
showed that the amphiphilic adsorbent had a high adsorp-
tion capacity for LDL without significantly adsorbing high- 
density lipoprotein. The adsorption capacity of the adsor-
bent for the removal of LDL, total cholesterol (TC) and TG 
was 1.916, 2.132, 1.349 mg/mL, respectively. After 2 h 
hemoperfusion on hyperlipidemia rabbits, the LDL levels 
from 3.619±0.354 decreased to 0.724±0.07 mmol/L, demon-
strating the adsorbent could effectively remove LDL [26].  
3  Polyvinyl alcohol based adsorbent 
Polyvinyl alcohol has been widely used in biomedical ap-
plications and has good blood compatibility. Macroporous 
polyvinyl alcohol microspheres were prepared and L-phe-     
nylalanine was immobilized as the ligand. The adsorbent 
could remove high levels of rheumatoid factors (RFs) from 
the blood of rheumatoid arthritis patients at a capacity of 
750 IU/mL [27].  
A series of bilirubin adsorbents were generated by link-
ing of trimethylamine, triethylamine and 1,6-hexanediamine 
on macroporous polyvinyl alcohol beads. The adsorption 
capacity of bilirubin reached 80% [28,29]. 
Recently adsorbents for sepsis were prepared by incor-
porating hexane diamine onto macroporous polyvinyl alco-
hol microspheres. The adsorbents had high adsorption effi-
ciencies for TNF- (72%), IL-6 (91%) and endotoxin (96%).  
4  Polymethylmethacrylate (PMMA ) based  
adsorbent 
Various adsorbents have been investigated for removing 
endotoxin from protein solutions by PMMA based adsor-
bents coupling with dimethylamine ligand. Experimental 
results indicated that the adsorbent having a hydroxyl group 
at the beta-site of the ligand had an enhanced adsorption 
capacity for endotoxin. The computer simulation showed 
that the hydroxyl group at the beta-site could form hydrogen 
bonds with endotoxin, as a result an octatomic ring was 
formed. The spacer of the adsorbent and the long alkyl 
chain of endotoxin were located at the same side of the oc-
tatomic ring. In this situation, electrostatic interaction, hy-
drogen bond, cooperative effect of octatomic ring and hy-
drophobic intermolecular interaction effected simultane-
ously. The combination of endotoxin with adsorbent was 
tight and adsorption capacity was effectively increased [30]. 
5  Adsorbents with other matrixes and ligands 
Agar or agrose was covalent linked on heat aggregated hu-
man IgG as ligand for the removal of rheumatoid factor. 
The adsorbent capacity for IgMRF, IgGRF, IgARF was 
3400, 2240, and 2400 IU/g respectively [31].  
Chitosan based adsorbent was also studied for the re-
moval of LDL adsorption with a capacity of 2.72 mg/mL 
[32].  
6  Molecular recognition mechanism between 
ligand and toxic molecules 
In general, there are four types of interacting forces in-
volved between the ligand and the toxic molecules i.e. elec-
trostatic interaction, hydrophobic interaction, hydrogen 
bonding and Van der Waals’force. The author found that 
electrostatic force plays an important role and enhance the 
adsorption capacity drastically in the case where the toxic 
molecule to be removed has a high polarity [32,33]. Hydro-
phobic interaction is crucially important in the case where the 
ligand and toxic molecule are non polar [34]. Antibody- 
antigen interaction contributes to the specificity between the 
molecular recognition. Computer modeling was also used to 
study the reaction mechanism [31–35]. These findings at-
tribute to the designing of more efficient adsorbent.  
7  Spacer effect 
The spacers have a significant effect on the adsorption 
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property of resin adsorbents. It can reduce the steric hin-
drance between the ligand and the large toxic molecules, 
resulting in an increase of adsorption capacity of the adsor-
bent. Different spacers have an obvious effect on the ad-
sorption properties of adsorbents. When IgG was coupled 
by N,N′-carbonyldiimidazole (CDI), the immuno-adsorbent 
had an adsorption efficiency of 30%–35% for IgA in vitro 
experiments [36]. When it was coupled by glycidyl 1,4- 
butanediol, the adsorption efficiency was 60% which was 
much higher than that of CDI coupling method [37]. And 
when it was coupled by epoxy chloropropane and glutaral-
dehyde, the adsorbent efficiency reached 74% [38].  
The length of a spacer (number of carbon atoms) influ-
ences significantly the adsorption capacity of the resin. As 
shown in Figure 1 the adsorption capacity increases as the 
number of carbon atoms increased (about 12%) [17]. Spacer, 
not only has a profound effect on the performance of ad-
sorbents, recently it was also shown that it could increase 
the adhesion of biological cells to the matrix.  
8  Scale-up production and clinical performance 
In China, at present there are 5–6 companies engaged in the 
production of adsorbents on an industrial scale of which 
Jianfan Biological Science and Technology Company in 
Zhuhai is the largest. They used the technology and patents 
provided by the Nankai group, several products were pro-
duced for the treatment of SLE, hyperbilirubinemia, uremia 
and various acute intoxication patients by whole blood hemo-      
perfusion. Statistic studies provided by Jianfan Biological 
Science and Technology Company, shown that more than 
200000 cartridges were produced yearly and used in 2300 
hospitals in China. The productive value was over 200 mil-
lion RMB (~3.2 million USD). Furthermore, new adsor-
bents were developed for the treatment of sepsis and multi- 
failure organs. Going back to the 1980s, when the adsor-
bents were produced and clinical trials needed to be per-
formed, but the medical doctors at that time did not recog-
nize the techniques of sorption perfusion and refused to 
carry out clinical trials. So the first trial was carried on an  
 
Figure 1  The effect of spacer length on the adsorption property of resin 
adsorbents. 
acute intoxicated patient who was in deep coma with heart 
beads permanently stopped and on a young woman suffer-
ing from severe SLE (coma grade II) complicated with re-
nal failure. Life saving and recovery of patients encouraged 
doctors to continue further clinical trials. Other difficulties 
arose from the company that was to maintain the quality of 
the adsorbents in scale up production which the Nankai group 
helped and gave instructions. Marketing is crucially im-
portant to recoup millions of capital outlay. Various measures 
and issues were conducted such as organizing teaching 
courses, training classes for doctors and product exhibitions 
were displayed to advertise and teach the new sorption 
technology. A new method for the treatment of severe dis-
eases was achieved after more than 10 years of persisting 
effort in scaling up production and clinical trials. Clinical 
performances have proved that it is beneficial in enhancing 
the life quality of patients. Up to date, whole blood sorption 
therapy was performed on hundreds and thousands of pa-
tients suffering autoimmune diseases, various cases of acute 
intoxication such as suicidal, drug overdose, accidental con-
tact of organo-phosphorous insecticides, snake poison or 
miss taking puffer fish (tetrodotoxin) were successfully 
treated. Symptoms were relieved, lives were saved, no sig-
nificant side effects have occurred and an efficiency of 90% 
was achieved. More important was that whole blood perfu-
sion with locally produced adsorbents are cost-effective. A 
cartridge of a few hundred USD is available, so a large 
number of patients are able to afford it, which drastically 
reduces the high medical burden of health-care agencies.  
9  Concluding remarks and perspectives 
Thirty years of research and development in adsorbents for 
whole blood purification is well established in China for the 
treatment of autoimmune diseases, hyperbilirubinemia, ure-
mia and various acute intoxication patients. Clinical per-
formances have proved that it is safe, efficient and cost ef-
fective. In the future, clinical performance of large pore size, 
tailor made resin adsorbents would have a high efficiency 
for the removal of cytokines in sepsis. Investigation in the 
removal of pathogenic virus by adsorbents with specific 
ligands has a high impact in blood purification.  
For the outstanding achievement, the Nankai group was rewarded the 
National prize of Scientific and Technological Progress, the Ho Leung Ho 
Lee prize, the Chinese Invention prize and the Special Contribution Prize 
of the 9th World Biomaterial Congress. At this point, we are grateful to our 
national and local governmental departments who have financially sup-
ported the Nankai research group for so many years. Sincerely thanks goes 
to the local and international colleagues for their strong scientific supports 
and assistance. 
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